Amylyx Pharmaceuticals Inc (AMLX) financials
Amylyx Pharmaceuticals revenue and earnings by year
Amylyx Pharmaceuticals's revenue was $87.4 million in the fiscal year to December 31, 2024, down 77.1% from the year before. Net income was -$302 million, -345.4% of revenue. Since the fiscal year to December 31, 2019, revenue has grown 127.7% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 6 fiscal years
| Fiscal year to | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
| Revenue | 87 | 381 | 22 | 0 | 1 | 1 |
| Revenue growth | -77.1% | 1612.9% | 7700.0% | -56.2% | -54.4% | — |
| Gross profit | -37 | 355 | 19 | — | — | — |
| Gross margin | -42.6% | 93.3% | 86.5% | — | — | — |
| Operating income | -315 | 39 | -201 | -83 | -39 | -14 |
| Operating margin | -360.2% | 10.2% | -905.7% | -29013.3% | -6000.8% | -950.5% |
| Net income | -302 | 49 | -198 | -88 | -42 | -14 |
| Net margin | -345.4% | 12.9% | -892.4% | -30853.0% | -6504.6% | -961.9% |
| Diluted EPS | -$4.43 | $0.70 | -$3.39 | -$13.31 | — | — |
| Free cash flow | -168 | 11 | -182 | -75 | -37 | -11 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open AMLX in Markets.
See also: AMLX returns
No forecast, no recommendation. This page describes Amylyx Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.